Cancer-related direct-to-consumer advertising: a critical review.
The direct-to-consumer advertising (DTCA) phenomenon has received attention because of its attempt to reach out to consumers by bypassing important gatekeepers such as physicians. The emergence of new information platforms and the introduction of genetic tests directly to the consumer have heightened the concern with DTCA and its potential consequences. These effects of DTCA are particularly important given the communication inequalities among social groups, with class, race and ethnicity influencing how people access, seek, process and act on information. This Science and Society article reviews the major issues regarding general and cancer-related DTCA and also offers data from a national survey in the United States as an example of the communication inequalities in genetic testing awareness.
Lung Cancer Disparities Center, Harvard University, School of Public Health Department of Society, Human Development and Health, Boston MA 02215, USA.
Emily Z
EZ
Kontos
K
K
Viswanath
D000329:Advertising; D000970:Antineoplastic Agents; D005820:Genetic Testing; D033161:Government Regulation; D057220:Health Literacy; D054625:Healthcare Disparities; D006801:Humans; D033181:Information Dissemination; D020407:Internet; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics*; D014481:United States
D000970:Antineoplastic Agents
New Genet Soc. 2006 Apr;25(1):89-107
17312631
Am J Health Syst Pharm. 2005 Mar 15;62(6):620-5
15757884
Am J Manag Care. 2005 Oct;11(10):601-8
16232001
Am J Public Health. 2009 Mar;99(3):442-5
19106425
J Gen Intern Med. 1999 Nov;14(11):651-7
10571712
Health Commun. 2006;20(2):131-9
16965250
Annu Rev Genomics Hum Genet. 2008;9:161-82
18767961
J Clin Oncol. 2009 Sep 1;27(25):4182-7
19652071
Patient Educ Couns. 2004 Nov;55(2):293-300
15530767
Genet Med. 2005 Sep;7(7):514; author reply 514
16170245
BMJ. 2000 Apr 29;320(7243):1200-4
10784551
J Fam Pract. 2000 Dec;49(12):1092-8
11132058
Genet Med. 2005 Mar;7(3):191-7
15775755
Health Psychol. 2009 Jul;28(4):510-8
19594276
Oncologist. 2006 Feb;11(2):217-26
16476842
Genet Med. 2008 Dec;10(12):888-94
19092441
JAMA. 2002 Oct 9;288(14):1762-7
12365961
BMJ. 2006 Jun 24;332(7556):1469
16793793
Ann Fam Med. 2007 Jan-Feb;5(1):6-13
17261859
BMJ. 2007 Mar 31;334(7595):664-6
17395944
J Biolaw Bus. 2001;4(4):59-65
12751498
Pharmacoeconomics. 2002;20 Suppl 3:77-85
12457428
J Clin Oncol. 2003 Sep 1;21(17):3191-3
12874271
Nat Rev Cancer. 2005 Oct;5(10):828-35
16195753
J Fam Pract. 2000 Apr;49(4):329-35
10778839
J Clin Oncol. 2007 Apr 1;25(10):1267-71
17401016
Health Mark Q. 2009 Jan-Mar;26(1):42-55
19197587
J Health Commun. 2004 Nov-Dec;9(6):529-40
15764451
J Health Commun. 2005 Oct-Nov;10(7):609-19
16278198
Minn Med. 2010 Mar;93(3):50-2
20429178
J Fam Pract. 1997 Dec;45(6):495-9
9420585
Health Mark Q. 2007;24(1-2):77-91
19042521
J Health Commun. 2010;15 Suppl 3:216-35
21154095
J Clin Pharmacol. 2009 Aug;49(8):886-8
19602717
Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):957-64
10566549
Ann Intern Med. 2005 Sep 6;143(5):355-61
16144894
Cancer Causes Control. 2005 Feb;16(1):5-14
15750853
J Health Commun. 2004 Nov-Dec;9(6):499-513
15764449